SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nancy S. Reau, Eli J. Korner, Jian Han, Donald Jensen, Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin, Current Hepatology Reports, 2015, 14, 1, 53

    CrossRef

  2. 2
    Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Odile Goria, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Catherine Buffet, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capron, Gérard Thiefin, Sophie Hillaire, Vincent Di Martino, Pierre Nahon, Sylvie Chevret, Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort), Hepatology, 2015, 61, 4
  3. 3
    Heidar Sharafi, Seyed Moayed Alavian, Maryam Keshvari, Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1, Hepatitis Monthly, 2015, 15, 1

    CrossRef

  4. 4
    Savino Bruno, Alex J. Thompson, Rosina Critelli, Andrea Crosignani, Sonia Rossi, Stefania De Lisi, Elisabetta Cariani, Paola Zermiani, Valentina Vaira, Vincenzo Boccaccio, Patrick Maisonneuve, Erica Villa, Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: A long-term cohort study, Antiviral Research, 2015, 113, 27

    CrossRef

  5. 5
    Ann-Sofi Duberg, Sarah Blach, Karolin Falconer, Martin Kåberg, Homie Razavi, Soo Aleman, The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies, Scandinavian Journal of Gastroenterology, 2015, 50, 2, 233

    CrossRef

  6. 6
    José Velosa, Fátima Serejo, Fernando Ramalho, Rui Marinho, Beatriz Rodrigues, Cilénia Baldaia, Miguel Raimundo, Paula Ferreira, A practical guide for antiviral therapy of chronic Hepatitis C, GE Portuguese Journal of Gastroenterology, 2014, 21, 6, 221

    CrossRef

  7. 7
    Angelo Andriulli, Alessandra Nardi, Vito Di Marco, Antonio Massimo Ippolito, Caius Gavrila, Alessio Aghemo, Daniele Di Paolo, Giovanni Squadrito, Eleonora Grassi, Vincenza Calvaruso, Maria Rosa Valvano, Giuseppina Brancaccio, Antonio Craxi, Mario Angelico, An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C, Digestive and Liver Disease, 2014, 46, 9, 818

    CrossRef

  8. 8
    A. H. Miners, N. K. Martin, A. Ghosh, M. Hickman, P. Vickerman, Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research, Journal of Viral Hepatitis, 2014, 21, 9
  9. 9
    V. W.-S. Wong, C.-J. Liu, Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals, Alimentary Pharmacology & Therapeutics, 2014, 39, 12
  10. 10
    S. Saab, S. C. Gordon, H. Park, M. Sulkowski, A. Ahmed, Z. Younossi, Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection, Alimentary Pharmacology & Therapeutics, 2014, 40, 6
  11. 11
    Christophe Hézode, Helene Fontaine, Celine Dorival, Fabien Zoulim, Dominique Larrey, Valerie Canva, Victor De Ledinghen, Thierry Poynard, Didier Samuel, Marc Bourliere, Laurent Alric, Jean–Jacques Raabe, Jean–Pierre Zarski, Patrick Marcellin, Ghassan Riachi, Pierre–Henri Bernard, Veronique Loustaud–Ratti, Olivier Chazouilleres, Armand Abergel, Dominique Guyader, Sophie Metivier, Albert Tran, Vincent Di Martino, Xavier Causse, Thong Dao, Damien Lucidarme, Isabelle Portal, Patrice Cacoub, Jerome Gournay, Veronique Grando–Lemaire, Patrick Hillon, Pierre Attali, Thierry Fontanges, Isabelle Rosa, Ventzislava Petrov–Sanchez, Yoann Barthe, Jean–Michel Pawlotsky, Stanislas Pol, Fabrice Carrat, Jean–Pierre Bronowicki, Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis, Gastroenterology, 2014, 147, 1, 132

    CrossRef

  12. 12
    Tarik Asselah, Savino Bruno, Antonio Craxi, HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?, Journal of Hepatology, 2014, 61, 6, 1430

    CrossRef

  13. You have free access to this content13
    Vincenzo Boccaccio, Savino Bruno, Management of HCV patients with cirrhosis with direct acting antivirals, Liver International, 2014, 34,
  14. 14
    Giovanni Faria Silva, Cristiane A. Villela-Nogueira, Carlos Eduardo Brandão Mello, Elza Cotrim Soares, Henrique Sergio M. Coelho, Paulo Roberto Abrão Ferreira, Fernando José Goes Ruiz, Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study, The Brazilian Journal of Infectious Diseases, 2014, 18, 1, 48

    CrossRef

  15. 15
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Yoshiyuki Narahara, Katsuhiko Iwakiri, Katsuhisa Nakatsuka, Chiaki Kawamoto, Choitsu Sakamoto, Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load, Hepatology Research, 2014, 44, 13
  16. 16
    Sylvie Deuffic-Burban, Michaël Schwarzinger, Dorothée Obach, Vincent Mallet, Stanislas Pol, Georges-Philippe Pageaux, Valérie Canva, Pierre Deltenre, Françoise Roudot-Thoraval, Dominique Larrey, Daniel Dhumeaux, Philippe Mathurin, Yazdan Yazdanpanah, Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141), Journal of Hepatology, 2014, 61, 1, 7

    CrossRef

  17. 17
    Christoph Höner zu Siederdissen, Markus Cornberg, Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection, Clinical Investigation, 2014, 4, 4, 361

    CrossRef

  18. 18
    Silvia Odolini, Silvia Amadasi, Carlo Cerini, Mariarosaria Giralda, Paola Nasta, Francesco Castelli, Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV, BMC Infectious Diseases, 2014, 14, Suppl 5, S4

    CrossRef

  19. 19
    Barbara Coco, Paolo Caraceni, Alessio Aghemo, Davide Bitetto, Raffaele Bruno, Alessia Ciancio, Marco Marzioni, Salvatore Petta, Maria Rendina, Luca Valenti, Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF), Digestive and Liver Disease, 2014, 46, 1, 18

    CrossRef

  20. 20
    Ya-Chi Chen, Coen Bernaards, Rohit Kulkarni, Sebastian Moreira, Yonghong Zhu, Anna Chan, Ethan Badman, Andrew Ackrill, James Thommes, Patrick F. Smith, Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies, British Journal of Clinical Pharmacology, 2014, 78, 3
  21. 21
    Hyun Seok Lee, Young Oh Kweon, Won Young Tak, Soo Young Park, Eun Jung Kang, Yu Lim Lee, Hae Min Yang, Hyun Woo Park, Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients, Clinical and Molecular Hepatology, 2013, 19, 2, 148

    CrossRef

  22. 22
    Christoph Hoener zu Siederdissen, Markus Cornberg, Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3, Current Hepatitis Reports, 2013, 12, 4, 261

    CrossRef

  23. 23
    Savino Bruno, John M. Vierling, Rafael Esteban, Lisa M. Nyberg, Hugo Tanno, Zachary Goodman, Fred Poordad, Bruce Bacon, Keith Gottesdiener, Lisa D. Pedicone, Janice K. Albrecht, Clifford A. Brass, Seth Thompson, Margaret H. Burroughs, Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis, Journal of Hepatology, 2013, 58, 3, 479

    CrossRef

  24. You have free access to this content24
    Guidelines for the Management of Hepatitis C Virus Infection, Hepatology Research, 2013, 43, 1
  25. You have free access to this content25
    Eleonora Grassi, Alessio Aghemo, How to optimize HCV therapy in genotype 2 patients, Liver International, 2013, 33,
  26. 26
    Hideyuki Tamai, Kosaku Moribata, Yoshiyuki Mori, Naoki Shingaki, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masao Ichinose, Low-dose pegylated interferon-alpha-2a monotherapy in elderly and/or cirrhotic patients infected with hepatitis C virus genotype-2 or genotype-1 low level infection, Hepatology Research, 2013, 43, 7
  27. 27
    Manie Juneja, Rebekah Euliano, Rohit Satoskar, James H. Lewis, Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis, Digestive Diseases and Sciences, 2013, 58, 11, 3348

    CrossRef

  28. You have free access to this content28
    D. Joshi, I. Carey, K. Agarwal, Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients, Alimentary Pharmacology & Therapeutics, 2013, 37, 7
  29. 29
    Phil McEwan, Thomas Ward, Yong Yuan, Ray Kim, Gilbert L'Italien, The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States, Hepatology, 2013, 58, 1
  30. 30
    Kosh Agarwal, Ashley Barnabas, Treatment of chronic hepatitis C virus infection after liver transplantation, Digestive and Liver Disease, 2013, 45, S349

    CrossRef

  31. 31
    Christophe Hézode, Hélène Fontaine, Céline Dorival, Dominique Larrey, Fabien Zoulim, Valérie Canva, Victor de Ledinghen, Thierry Poynard, Didier Samuel, Marc Bourlière, Jean-Pierre Zarski, Jean-Jacques Raabe, Laurent Alric, Patrick Marcellin, Ghassan Riachi, Pierre-Henri Bernard, Véronique Loustaud-Ratti, Sophie Métivier, Albert Tran, Lawrence Serfaty, Armand Abergel, Xavier Causse, Vincent Di Martino, Dominique Guyader, Damien Lucidarme, Véronique Grando-Lemaire, Patrick Hillon, Cyrille Feray, Thong Dao, Patrice Cacoub, Isabelle Rosa, Pierre Attali, Ventzislava Petrov-Sanchez, Yoann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat, Jean-Pierre Bronowicki, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890, Journal of Hepatology, 2013, 59, 3, 434

    CrossRef

  32. 32
    A. Mangia, L. Mottola, V. Piazzolla, Update on the Treatment of Patients With Non-Genotype 1 Hepatitis C Virus Infection, Clinical Infectious Diseases, 2013, 56, 9, 1294

    CrossRef

  33. 33
    Paul M Trembling, Sudeep Tanwar, Geoffrey M Dusheiko, Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection, Expert Review of Anti-infective Therapy, 2012, 10, 3, 269

    CrossRef

  34. 34
    Michelle Lai, Nezam H. Afdhal, Clinical utility of interleukin-28B testing in patients with genotype 1, Hepatology, 2012, 56, 1
  35. 35
    Lisa J. McGarry, Vivek S. Pawar, Hemangi R. Panchmatia, Jaime L. Rubin, Gary L. Davis, Zobair M. Younossi, James C. Capretta, Michael J. O'Grady, Milton C. Weinstein, Economic model of a birth cohort screening program for hepatitis C virus, Hepatology, 2012, 55, 5
  36. 36
    Marc Bourlière, Asma Khaloun, Claire Wartelle-Bladou, Valérie Oules, Isabelle Portal, Souad Benali, Xavier Adhoute, Paul Castellani, Future treatment of patients with HCV cirrhosis, Liver International, 2012, 32,
  37. 37
    Sudeep Tanwar, Paul M. Trembling, Geoffrey M. Dusheiko, Hepatitis C Therapy: Lessons of the Last Two Decades, Current Hepatitis Reports, 2012, 11, 3, 119

    CrossRef

  38. You have free access to this content38
    Ranjeeta Bahirwani, K. Rajender Reddy, Hepatitis C viral infection in patients with cirrhosis, Clinical Liver Disease, 2012, 1, 3
  39. 39
    Bruno Roche, Didier Samuel, Hepatitis C virus treatment pre- and post-liver transplantation, Liver International, 2012, 32,
  40. 40
    Gian Maria Prati, Alessio Aghemo, Maria Grazia Rumi, Roberta D’Ambrosio, Stella De Nicola, Maria Francesca Donato, Elisabetta Degasperi, Massimo Colombo, Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis, Journal of Hepatology, 2012, 56, 2, 341

    CrossRef

  41. 41
    Ahmed A. El Khattib, Sara M. Abdelhakam, Dalia M. Ghoraba, Wesam A. Ibrahim, Moataz M. Sayed, Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis, European Journal of Internal Medicine, 2012, 23, 1, e34

    CrossRef

  42. 42
    José-Luis Calleja, Javier García-Samaniego, Belén Ruiz-Antorán, María Trapero, Rosa Morillas, Juan Revilla, José Carlos Erdozaín, María-Dolores Espinosa, Dolores Suárez, Ricard Solá, Manuel Romero-Gómez, Fernando Baños, Marco-Antonio Álvarez, Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels, Journal of Gastroenterology and Hepatology, 2012, 27, 11
  43. 43
    Tomohisa SAITO, Satofumi IIDA, Takehiko KAWANISHI, Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Platelet Decrease Induced by Peg-interferon-alpha 2a, Drug Metabolism and Pharmacokinetics, 2012, 27, 6, 614

    CrossRef

  44. 44
    Sudeep Tanwar, Mark Wright, Graham R. Foster, Stephen D. Ryder, Peter R. Mills, Matthew E. Cramp, Julie Parkes, William M. Rosenberg, Randomized clinical trial, European Journal of Gastroenterology & Hepatology, 2012, 24, 5, 543

    CrossRef

  45. 45
    J. A. Mira, S. Garcia-Rey, A. Rivero, I. de los Santos-Gil, L. F. Lopez-Cortes, J. A. Giron-Gonzalez, F. Tellez, M. Marquez, D. Merino, M. J. Rios-Villegas, J. Macias, A. Rivero-Juarez, J. A. Pineda, Response to Pegylated Interferon Plus Ribavirin Among HIV/Hepatitis C Virus-Coinfected Patients With Compensated Liver Cirrhosis, Clinical Infectious Diseases, 2012, 55, 12, 1719

    CrossRef

  46. 46
    Sudeep Tanwar, Paul M Trembling, Geoffrey M Dusheiko, TMC435 for the treatment of chronic hepatitisC, Expert Opinion on Investigational Drugs, 2012, 21, 8, 1193

    CrossRef

  47. 47
    Yasuhiro Asahina, Namiki Izumi, Makoto Oketani, Hiromitsu Kumada, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu, Hiroshi Yotsuyanagi, Treatment Guidelines of Hepatitis C, Kanzo, 2012, 53, 6, 355

    CrossRef

  48. 48
    Martin Lagging, Ann-Sofi Duberg, Rune Wejstål, Ola Weiland, Magnus Lindh, Soo Aleman, Filip Josephson, Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations, Scandinavian Journal of Infectious Diseases, 2012, 44, 7, 502

    CrossRef

  49. 49
    Roberta D’Ambrosio, Alessio Aghemo, Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks, Hepatitis Monthly, 2012, 12, 6, 361

    CrossRef

  50. 50
    Stevan A. Gonzalez, Consensus Interferon: Tailored Therapy and the Impact of Adherence, Digestive Diseases and Sciences, 2011, 56, 3, 631

    CrossRef

  51. 51
    Lionel Piroth, Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S75

    CrossRef

  52. 52
    José Velosa, Fátima Serejo, Rui Marinho, Joana Nunes, Helena Glória, Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis, Digestive Diseases and Sciences, 2011, 56, 6, 1853

    CrossRef

  53. 53
    Andrew Aronsohn, Donald Jensen, HCV Eradication: Implications for Disease Resolution, Current Hepatitis Reports, 2011, 10, 1, 27

    CrossRef

  54. 54
    Maria Ripoli, Valerio Pazienza, Impact of HCV genetic differences on pathobiology of disease, Expert Review of Anti-infective Therapy, 2011, 9, 9, 747

    CrossRef

  55. 55
    Elena Vezali, Alessio Aghemo, Massimo Colombo, Interferon in the treatment of chronic hepatitis C: a drug caught between past and future, Expert Opinion on Biological Therapy, 2011, 11, 3, 301

    CrossRef

  56. 56
    Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh, Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis, The Korean Journal of Hepatology, 2011, 17, 3, 220

    CrossRef

  57. 57
    Natalie Bzowej, David R. Nelson, Norah A. Terrault, Gregory T. Everson, Lichen L. Teng, Avinash Prabhakar, Michael R. Charlton, PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus, Liver Transplantation, 2011, 17, 5
  58. 58
    Michael W. Fried, Stephanos J. Hadziyannis, Mitchell L. Shiffman, Diethelm Messinger, Stefan Zeuzem, Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection, Journal of Hepatology, 2011, 55, 1, 69

    CrossRef

  59. 59
    Peter Ferenci, Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future, Expert Opinion on Drug Safety, 2011, 10, 4, 529

    CrossRef

  60. 60
    Marie-Luise Berres, Christian Trautwein, Maximilian Schmeding, Dennis Eurich, Frank Tacke, Marcus Bahra, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth, Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection, Hepatology, 2011, 53, 2
  61. 61
    P. Guillouche, C. Féray, Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation, Alimentary Pharmacology & Therapeutics, 2011, 33, 2
  62. 62
    Elena Vezali, Alessio Aghemo, Massimo Colombo, A review of the treatment of chronic hepatitis C virus infection in cirrhosis, Clinical Therapeutics, 2010, 32, 13, 2117

    CrossRef

  63. 63
    Raymond T. Chung, Fred F. Poordad, Tarek Hassanein, Xiaolei Zhou, Ellen Lentz, Avinash Prabhakar, Adrian M. Di Bisceglie, Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C, Hepatology, 2010, 52, 6
  64. 64
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2010, 19, 8
  65. 65
    D.M. Harnois, Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis, Yearbook of Medicine, 2010, 2010, 472

    CrossRef

  66. 66
    D.M. Harnois, Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis, Yearbook of Gastroenterology, 2010, 2010, 228

    CrossRef

  67. You have free access to this content67
    Richard K. Sterling, Long-term effects of sustained virologic response on the development of esophageal varices in compensated cirrhosis: “Is the bang worth the buck?”, Hepatology, 2010, 51, 6
  68. 68
    Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo, Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2010, 7, 9, 485

    CrossRef

  69. 69
    Xavier Forns, Jordi Bruix, Treating hepatitis C in patients with cirrhosis: The effort is worth it, Journal of Hepatology, 2010, 52, 5, 624

    CrossRef

  70. 70
    Mike Makris, Geoffrey Dusheiko, Hepatitis and Hemophilia,
  71. 71
    Jama M. Darling, Stanley M. Lemon, Michael W. Fried, Hepatitis C,
  72. 72
    Alyson N. Fox, Lennox J. Jeffers, Rajender Reddy, Liver Biopsy and Laparoscopy,